Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies

Journal:: Nature Communications
Published:: 2026-05-06
DOI:: 10.1038/s41467-026-72635-x
Affiliations:: 2
Authors:: 21

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	21.000000 21.000000 21.000000	1.00

Interested in Oncology and Carcinogenesis?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Regenerative medicine

Regenerative medicine has the potential to transform the treatment of chronic and life-threatening diseases. But major challenges remain, such as overcoming immune rejection and ensuring that new therapies are developed using more inclusive data sets. In this supplement, we explore the discoveries that are driving the field, the barriers that could limit its progress, and the teams and institutions that are making their mark.

Access free

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Research highlights of partners

Nonlinear materials add another dimension to light scattering

Institute for Basic Science (IBS)
26 Dec 2023
Ants’ venom contains neurotoxins

The University of Queensland (UQ)
31 Oct 2023
How ribosome subunit is exported from the nucleus

Southern University of Science and Technology (SUSTech)
29 Sep 2023

Research highlights